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ImmunotherapyThe number of elderly patients with renal cell carcinoma is rising. Elderly patients differ from their
younger counterparts in, among others, higher incidence of comorbidity and reduced organ function.
Age influences outcome of surgery, and therefore has to be taken into account in elderly patients eligible
for cytoreductive nephrectomy. Over the last decade several novel effective drugs have become available
for the metastatic setting targeting angiogenesis and mammalian target of rapamycin. Immune
checkpoint blockade with a programmed death 1 antibody has recently been shown to increase survival
and further studies with immune checkpoint inhibitors are ongoing. In this review we summarize the
available data on efficacy and toxicity of existing and emerging therapies for metastatic renal cell
carcinoma in the elderly. Where possible, we provide evidence-based recommendations for treatment
choices in elderly.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Approximately one half of the patients who are diagnosed with
renal cell carcinoma (RCC) are aged 65 years or more and almost a
quarter is over 75 years of age. Given the global increase of life
expectancy, the number of elderly patients with RCC will increase
significantly in the near future [1]. In 2012 it was estimated that
338,000 patients were newly diagnosed with kidney cancer world-
wide, which equals 2.4% of all cancers and an age-specific rate of
4.4 per 100,000 population [2]. In general, elderly is defined as
individuals over 65 years of age. But it may be more meaningful
to further divide elderly into three age groups namely younger-
old (65–74 years), mid-old (75–84), and old–old (P85 years) [3].
Moreover, chronological age alone is not very informative for
clinical decision-making. Since the ‘90 s, an increase in use of terms
like ‘frailty’ or ‘biological age’ indicates that clinicians prefer to
classify patients rather according to functional characteristics than
to age alone [4]. Frailty is a state of vulnerability to poor resolutionof homeostasis following a stressor event, such as nephrectomy or
systemic anti-cancer treatment [5]. Frailty in older patients with
any stage of solid or hematological malignancy ranges from 6%
to 86% [6]. Frail patients and patients with pre-frailty have an
increased risk of all-cause mortality, postoperative complications
and mortality and chemotherapy intolerance. Across trials, a
remarkable range of cut-off points and several different
approaches to identify frailty have been used [6]. However, geri-
atric assessments have seldom been incorporated in phase III can-
cer trials. This may be due to lack of validation of these
instruments. Currently there is neither solid evidence designating
the best type of geriatric assessment tool nor whether outcome
is improved by applying these instruments in older cancer
patients. Nonetheless, the National Comprehensive Cancer Net-
work (NCCN) guideline for elderly recommends using a compre-
hensive geriatric assessment (CGA) [7]. Additional studies are
warranted for validation of such tools [8]. There are important
differences between elderly and younger individuals that can
potentially affect tolerance of treatment. Firstly, a decline in
normal organ function can result in different drug metabolism
and clearance. Kidney function for example starts declining at
the age of 40. This limited reserve capacity is a factor to take into
account when considering a tumor nephrectomy. A reduced
pulmonary or cardiac function in turn, may complicate surgical
64 R.R.H. van den Brom et al. / Cancer Treatment Reviews 46 (2016) 63–72treatment. Secondly, aging comes with physiologic changes such as
a relative increase of body fat, reduced water content and reduced
muscle mass, which influences drug distribution. Furthermore,
elderly patients are likely to be prescribed multiple drugs for
co-morbid conditions, resulting in potential interactions with renal
cancer treatment. Finally, elderly patients who look back on a
fulfilled life might have a different perception and acceptation of
cancer diagnosis and appreciation of cancer treatment side effects
compared to younger individuals, which might result in different
decision-making [9].
Traditionally, systemic treatment for metastatic renal cell
carcinoma (mRCC) consisted of cytokine therapy. The value of
cytoreductive nephrectomy is well established in this setting. Over
the last decade, therapies targeting the vascular endothelial
growth factor A (VEGF-A) pathway and mammalian target of
rapamycin (mTOR) have been the mainstay of treatment. Recently
the programmed death 1 (PD-1) antibody nivolumab was shown
to increase overall survival after VEGF-A targeting therapy com-
pared to the mTOR inhibitor everolimus. Several studies testing
immune checkpoint inhibitors alone or in combination in mRCC
are ongoing. It is unknown whether age-related changes of the
immune system like immune exhaustion affect the efficacy of
immunotherapy in elderly patients.
Specific information on how to treat elderly patients with mRCC
is scarce. This is the consequence of a disproportionate small share
of elderly patients in clinical trials [10]. The percentage of elderly
enrolled in cancer drug registration trials between 1992 and
2002 was 36, 20, and 9 for patients aged over 65, 70, and 75 years,
whereas the corresponding estimated percentages of cancer
patients in the US were 60, 46, and 31 respectively [11]. Despite
acknowledging this underrepresentation and recommendations
to increase enrollment of elderly patients in clinical trials, similar
percentages were accrued in more recent registration trials
between 2007 and 2010 [12]. An important reason for underrepre-
sentation of elderly patients in clinical trials is that exclusion crite-
ria often comprise co-morbidity, reduced performance status, use
of certain medications and impaired functional organ capacity,
resulting in ineligibility of many elderly patients. Furthermore,
physicians’ perception that older patients are at higher risk for
toxicity and are less likely to benefit from treatment has con-
tributed to the low accrual rate for older patients [13]. Physician
surveys revealed that co-morbid conditions and fear for toxic effects
of treatment are the most frequently cited barriers to recruitment of
older patients [14,15]. Consequently, the elderly patients who do
participate in clinical trials do not represent the general elderly
patient population and trial results cannot be generalized to daily
practice without caution. The aim of this review is to summarize
the available data for efficacy, complication risk and toxicity of
surgical and approved systemic treatment for elderly mRCC
patients. In this era with multiple treatment options available, tools
to guide treatment decisions are extremely useful. Simultaneously,
different rating scales for systemic treatments have been developed
by NCCN, European Society for Medical Oncology (ESMO) and Amer-
ican Society of Clinical Oncology (ASCO) [16–18]. In this article, we
present modified NCCN evidence blocks as an example to visualize
the available data in elderly and to support treatment choices for
this subgroup. In addition, we describe the influence of aging on
the immune system and discuss the potential implications for treat-
ment of elderly patients with novel immune-modulating agents.
Search strategy
Data for this review consists of reports of phase III clinical trials
and expanded access programs of approved drugs for mRCC.
In addition, we performed a search in PubMed and used
references from relevant articles using the search terms ‘‘kidneycancer/renal (cell) carcinoma”, ‘‘elderly”, ‘‘age/aging”, ‘‘PD-1”, ‘‘PD-
L1”, ‘‘CTLA-4” and ‘‘immune checkpoint”. Only articles published in
English between 1990 and November 2015 were considered.
Applicable abstracts presented in 2014 and 2015 at ASCO annual,
ASCO GU and ESMO meetings concerning CTLA-4, PD-1 and PD-L1
inhibitors in RCC patients were added. The NCCN guidelines ‘‘kidney
cancer” (version 2.2016) and ‘‘Older Adult Oncology” (version
1.2016) and the European Association of Urology (EAU) and ESMO
guidelines on renal cell carcinoma of respectively 2015 and 2014
were used.Prognosis of elderly mRCC patients
Large studies from the US, Japan and Europe together compris-
ing almost 13,000 patients show that age is an independent
prognostic factor of survival in patients with RCC [19–21].
However, for mRCC this is only the case for low-grade tumors.
The effect of age becomes secondary to disease characteristics in
patients with stage II–IV or high-grade tumors [22].
The immune system plays a critical role in disease control and
activity and has traditionally been the target for systemic RCC
treatment [23]. With aging, immune senescence and immune
exhaustion may occur [24]. However, there is little evidence of a
causal relation between age-associated changes of the immune
system and development and progression of cancer [25,26].Cytoreductive nephrectomy
mRCC patients with a potentially resectable primary tumor, no
brain metastases and an excellent performance status, could be
candidates for cytoreductive nephrectomy before commencing
systemic therapy according to the NCCN guidelines [27]. This is
based on two randomized trials in the pre-targeted therapy era,
where patients with mRCC treated with cytoreductive nephrec-
tomy followed by interferon-a2b had a median overall survival
(OS) benefit of 7 months compared to patients treated with
interferon-a2b alone [28,29]. It is still unclear whether cytoreduc-
tive nephrectomy results in a survival benefit when followed by
targeted therapy compared to targeted therapy alone. According
to the EAU, cytoreductive nephrectomy is recommended in
appropriately selected patients with mRCC [30], based on a
meta-analysis of two randomized studies [31]. In the ESMO
guidelines, similar recommendations are made [32]. In routine
practice, cytoreductive nephrectomy is recommended in patients
with good performance status and large primary tumors with
limited volumes of metastatic disease and for patients with a
symptomatic primary tumor.
A population based retrospective analysis of 328 Dutch mRCC
patients demonstrated that elderly patients were less likely to
undergo a cytoreductive nephrectomy (OR 0.95 per year increase)
[33]. An alarmingly high peri-operative mortality rate (PMR),
defined as death occurring within the first 30 days after cytoreduc-
tive nephrectomy or during the initial hospital stay, of 21% for
patients 75 years of age or older (n = 24) has been reported for
cytoreductive nephrectomy compared to 1.1% for younger patients
(n = 380) [34]. However, a population-based analysis of patients
treated with a cytoreductive nephrectomy between 1988 and
2004 (n = 24.535) demonstrated a 30-day PMR of 4.7% in patients
aged 70–79 years [35]. The highest PMR was recorded for patients
aged over 80 (8.2%). A retrospective analysis compared 504 mRCC
patients 75 years or older with 2796 younger counterparts and
showed a PMR of 4.8 versus 1.9% [36]. There was a higher rate of
postoperative complications, blood transfusions and prolonged
hospitalization in the elderly patient group. Another study in 180
patients over 80 years of age (range 80–92), undergoing partial
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[37], showed that 38.8% of the patients experienced one or more
complications, and six patients (3.3%) died as a consequence of
post-operative complications. Median hospitalization was 13 days
(range 4–60). An ECOG performance status of 2–4 and a glomerular
filtration rate less than 30 mL/min were independent risk factors
for post-operative morbidity. Recommendations: Taking into
account the lack of evidence of benefit of cytoreductive nephrec-
tomy when followed by targeted therapy, and the higher mortality
and morbidity in elderly patients, cytoreductive nephrectomy is
not advised for this group. Only in fit elderly mRCC patients with
a symptomatic primary tumor, limited metastatic burden and a
reasonable life expectancy, nephrectomy could be considered.Angiogenesis inhibitors
Angiogenesis is a prominent feature of RCC caused by mutation
or silencing of the Von Hippel-Lindau gene which is an early event
in the majority of RCC tumors. Lack of functional Von Hippel–
Lindau protein results in hypoxia inducible factor 1a (HIF-1a)
accumulation. HIF-1a regulates angiogenesis, tumor growth, cell
proliferation and metastatic spread, and glucose metabolism by
acting as a transcription factor for critical downstream effectors
including VEGF-A, platelet-derived growth factor (PDGF), epider-
mal growth factor receptor and insulin-like growth factor [38].
Inhibition of angiogenesis has become the mainstay of treatment
in patients with mRCC with clear cell histology. Bevacizumab is a
monoclonal antibody targeting VEGF-A and several tyrosine kinase
inhibitors (TKIs) inhibit the VEGF pathway at the VEGF receptor
(VEGFR) level.
Bevacizumab
By binding VEGF-A, bevacizumab prevents VEGF-A from acti-
vating VEGFR on endothelial cells. In a phase III study mRCC
patients were randomized to receive bevacizumab (10 mg/kg
intravenously every 2 weeks plus 9 million international units
(MIU) interferon-a2a subcutaneously three times weekly,
n = 327) or interferon-a2a plus placebo (n = 322) [39]. The
bevacizumab combination overall significantly increased the PFS,
with a hazard ratio (HR) of 0.77 (95% confidence interval (CI)
0.58–1.03) in the subgroup of patients P65 years (n = 239). For
patients <40 (n = 26) and 40–64 (n = 384) years of age, HR were
0.65 (0.28–1.52) and 0.54 (0.43–0.68) respectively (see Tables 1
and 2). No information on toxicity related to age was reported.
In another phase III trial, in which previously untreated mRCC
patients were randomly assigned to receive either bevacizumab
(10 mg/kg intravenously every 2 weeks) plus interferon-a2b (9
MIU subcutaneously three times weekly) or single agent
interferon-a2b, no subgroup analyses for PFS and toxicity stratified
for age were provided [40,41]. Separately, efficacy and safety data
for patients P65 years of the AVOREN trial [40] were reported.
Efficacy was equal for patients <65 (n = 410) and P65 (n = 239)
years of age. The incidence of adverse events was similar, however,
the incidence of gradeP3 adverse events was higher in de elderly.
They also experienced more fatigue and asthenia [42].
Sunitinib
Sunitinib is an orally administered multiple TKI of VEGFR, PDGF
receptors (PDGFR) and other receptor tyrosine kinases. A landmark
study in treatment-naive mRCC patients demonstrated a PFS
benefit of 6 months over interferon-a2a (11 versus 5 months) with
a HR of 0.42 that was similar for patients <65 years (n = 475) and
patients P65 years (n = 275) [43]. In an expanded access trial,4371 patients received open-label sunitinib [44]. Thirty-two
percent of the patients were 65 years or older. Response rate,
median PFS and median OS in this elderly subgroup were compa-
rable to the outcome of the entire study population. Also frequen-
cies of the most common grade 3–4 treatment-related adverse
events were similar (see Table 3).
Data from six trials were pooled to compare efficacy and toxic-
ity of sunitinib in mRCC patients over 70 years of age with that of
younger patients [45]. PFS and OS were comparable between the
groups. Older patients experienced more fatigue, cough, peripheral
edema, anemia, decreased appetite, weight decrease, dizziness,
hypothyroidism, dehydration, urinary tract infection and thrombo-
cytopenia. Older patients also had more grade 3 toxicity (68% ver-
sus 53%). On the other hand, patients younger than 70 years
experienced more often hand-foot syndrome, chest pain and hair
color changes. No difference in grade 4 toxicity or treatment
related deaths was observed. Retrospectively, 68 patients
P70 years of age who were treated with sunitinib were analyzed
for frailty and sunitinib efficacy and toxicity [46]. Although suni-
tinib was effective, early interruptions occurred frequently. The
rates of adverse events in this study were higher than the rates
found in the above mentioned expanded access trial [44] and
pooled data analysis [45]. No correlation was found between frailty
at CGA and toxicity or treatment response.
Sorafenib
Sorafenib is another TKI of VEGFR but also inhibits Raf kinases.
A PFS advantage for sorafenib over placebo was demonstrated in
mRCC patients who had progressive disease after one line of sys-
temic treatment (in 81% consisting of prior cytokine treatment)
[47]. A retrospective subgroup analysis on safety and efficacy in
patients P70 years (n = 115) compared to patients <70 years of
age (n = 787) has been published [48]. Median PFS was not affected
by age. The proportions of patients with a response or stable dis-
ease after 6 weeks of sorafenib were also similar for the two age
groups (83.5% and 84.3%, respectively) and superior to those who
received placebo (53.8% and 62.2%, respectively). More grade 3–4
adverse events occurred in elderly patients (45.7% versus 36.7%).
VEGFR-TKIs are known to be associated with cardiac toxicity in
up to 33.8% of the patients [49]. Fatal cardiac ischemia occurred
in 2 out of 115 older sorafenib treated patients in addition to one
patient with grade 3 left ventricular systolic dysfunction and one
patient with grade 4 cardiac ischemia. In 10 out of 787 younger
patients cardiac ischemia or infarction was observed, and three
patients developed left ventricular dysfunction. None of the
placebo-treated patients had cardiac adverse events. Treatment
was permanently discontinued in 8.1% of younger and 21.4% older
sorafenib-treated patients for toxicity. Most common reasons for
the older patients to discontinue sorafenib were gastrointestinal
(5.7%) and dermatological (4.3%) side effects. Additionally, dose
reductions were required in 11.3% of the younger and 21.4% of
the older sorafenib-treated patients. The time to self-reported
health status deterioration was delayed by sorafenib among both
older patients (121 days versus 85 days with placebo) and younger
patients (90 days versus 52 days with placebo).
In an expanded access study in Europe, 1159 patients received
sorafenib for mRCC in what the authors reported to be a ‘real-
world setting’ [50] and subgroup analyses for 883 patients
<70 years and 265 patients P70 years were performed. Although
there was a trend for longer PFS in older compared to younger
patients (8.0 versus 6.4 months), disease control rates at 8 and
12 weeks were similar. Sorafenib treatment was generally well
tolerated without major differences between both age groups,
apart from fatigue, which was more common in the elderly
patients (44% versus 31%).
Table 1
Progression free survival of approved systemic treatments for mRCC in elderly and non-elderly patients.
Trial Treatment Age of study population Progression Free Survival
Overall
study
Non-elderly Elderly
Bevacizumab + IFN vs
placebo + IFN [39] phase
III, 1st line
Bevacizumab plus IFN (n = 327) Median 61 years (range 30–82) 10.2 mo HR 0.63 (95% CI
0.52–0.75)
<40 years HR 0.65 (95% CI
0.28–1.52) 40–64 years HR
0.54 (95% CI 0.43–0.68)
P65 years HR 0.77 (95% CI 0.58–1.03)
Placebo plus IFN (n = 322) Median 60 years (range 18–81) 5.4 mo
Bevacizumab + IFN vs IFN [40]
phase III, 1st line
Bevacizumab plus IFN (n = 369) NR 8.5 mo (95% CI 7.5–9.7) HR 0.72 (95% CI
0.61–0.83)
NR NR
IFN (n = 363) 5.2 mo (95% CI 3.1–5.6)
Sunitinib vs IFN [43] phase III,
1st line
Sunitinib (n = 375) Median 62 years (range 27–87) HR 0.42 (95% CI 0.33–0.52) ‘‘Equal to elderly” ‘‘Equal to non-elderly”
IFN (n = 360) Median 59 years (range 34–85)
Sunitinib [44] expanded ac-
cess, P1st line
Sunitinib (n = 4371) P65 years: 32% 10.9 mo (95% CI 10.3–11.2) NR P65 years 11.3 mo (95% CI 10.7–12.3)
Sunitinib [45] pooled data,
P1st line
First line (n = 783) OverallP 70 years: 19% NR <70 years 9.9 mo (95% CI 8.3–
10.7)
P70 years 11.0 mo (95% CI 9.0–14.8)
Cytokine-refractory n = 276) <70 years 8.1 mo (95% CI 7.8–
8.7)
P70 years 8.4 mo (95% CI 6.3–14.3)
Sunitinib [46] review, P1st
line
Sunitinib (n = 68) Median 74 years range 70–88) NR NR 13.6 months
Sorafenib vs placebo [46] and
subset analysis [48] 2nd
line
Sorafenib (n = 451) Median 59 years, P 70 years: 12.7%, of
which 60.8% was assigned to sorafenib
HR 0.44 (95% CI 0.35–0.55) <70 years HR 0.55 (95% CI
0.47–0.66)
P70 years HR 0.43 (95% CI 0.26–0.69)
Placebo (n = 452)
Sorafenib [50] expanded ac-
cess, P2nd line
Sorafenib (n = 1150) Median 62 (range 18–84), P70: 23% 6.6 mo <70 years 6.4 mo P70 years 8.0 mo
Sorafenib [51] expanded ac-
cess, P1st line
Sorafenib (n = 2504) Median 63 (range 13–93) P 0 years:
29.4%
NR <70 years 35 weeks (95% CI:
33–46 weeks)
P70 years 42 weeks (95% CI: 36–48 weeks)
Pazopanib [53] hase III, 1st
line or post-cytokines
Pazopanib (n = 290) Median 59 years (range 28–85) HR 0.46 (95% CI 0.34–0.62) NR NR
Placebo (n = 145) Median 60 years (range 25–81)
Pazopanib vs sunitinib [54]
phase III, 1st line
Pazopanib (n = 557) Median 61 years (range 18–88) 8.4 mo (95% CI 8.3–10.9) HR  1.0 HR favors sunitinib, but CI crosses 1.0
Sunitinib (n = 553) Median 62 years (range 23–86) 9.5 mo (95% CI 8.3–11.1)
Axitinib vs sorafenib [55]
phase III, 1st line
Axitinib (n = 192) Median 58 years (range 23–83) 10.1 mo (95% CI 7.2–
12.1)
HR 0.77 (95% CI
0.56–1.05)
<65 years HR 0.80 (95% CI
0.60–1.24
P 65 years HR 0.68 (95% CI 0.33– .39)
Sorafenib (n = 96) Median 58 years (range 20–77) 6.5 mo (95% CI 4.7–8.3)
Axitinib vs sorafenib [56]
phase III, post sunitinib,
bevIFN, temsirolimus or
cytokines
Axitinib (n = 361) Median 61 years (range 20–82) HR 0.67 (95% CI 0.54–0.81) <65 years HR 0.68 (95% CI
0.53–0.86)
P 65 years HR 0.68 (95% CI 0.33– .39)
Sorafenib (n = 362) Median 61 years (range 22–80)
Everolimus vs placebo [58] Everolimus (n = 272) Median 61 years (range 27–85) HR 0.30 (95% CI 0.22–0.40) <65 years HR 0.32 P65 years HR 0.29
phase III, post TKI Placebo (n = 138) Median 60 years (range 29–79)
Everolimus vs placebo [59]
subgroup analysis of [59]
Everolimus (n = 277) P65 years: 36.8% /P70 years: 17.5% 4.9 mo HR 0.33 (95% CI
0.25–0.43)
NR P65 years
5.5 mo/
P70 years
5.1 mo
P65 years HR 0.33 (95% CI
0.21–0.51) /P 70 years HR
0.19 (95% CI 0.09–0.37)
Placebo (n = 139) 1.9 mo P65 years
2.2 mo/
P70 years
1.9 mo
Temsirolimus + bevacizumab
vs IFN + bevacizumab [63]
phase III, 1st line
Temsirolimus plus bevacizumab
(n = 400)
Median 59 years (range 22–87) 9.1 mo (95% CI 8.1–10.2) <65 years 9.2 mo (95% CI 8.1–
10.5)
P65 years 8.5 mo (95% CI 7.2–12.8)
IFN plus bevacizumab (n = 391) Median 58 years (range 23–81) 9.3 mo (95% CI 9.0–11.2) <65 years 9.1 mo (95% CI 7.4–
10.9)
P65 years 11.6 mo (95% CI 7.5–16.4)
Abbreviations: NR = not reported, HR = hazard ratio, CI = confidence interval, vs = versus mo = months, IFN = interferon, TKI = tyrosine kinase inhibitor.
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Table 2
Overall survival of approved systemic treatments for mRCC in elderly and non-elderly patients.
Trial Treatment Age of study
population
Overall Survival
Overall study Non-elderly Elderly
Bevacizumab + IFN vs IFN [40]
phase III, 1st line
Bevacizumab
plus IFN
(n = 369)
NR 18.3 mo (95%
CI 16.5–22.5)
HR 0.86
(95% CI
0.73–1.01)
<44.8 years
18.1 mo (95%
CI 14.1–21.7)
HR 0.803
(95% CI
0.639–
1.009)
>44.8 years
20.8 mo (95%
CI 16.4–27.1)
HR 0.951
(95% CI
0.750–
1.207)
IFN (n = 363) 17.4 mo (95%
CI 14.4–20.0)
<44.8 years
16.2 mo (95%
CI 13.4–20.0)
>44.8 years
18.8 mo (95%
CI 13.8–27.0)
Sunitinib [44] expanded access,
P1st line
Sunitinib
(n = 4371)
P65 years: 32% 18.4 mo (95% CI 17.4–19.2) NR P65 years 18.2 mo (95% CI
16.6–19.8)
Sunitinib [45] pooled data, P1st
line
First line
(n = 783)
Overall
P70 years: 19%
NR <70 years 23.6 mo (95% CI
21.2–27.6)
P70 years 25.6 mo (95% CI
21.7–38.4)
Cytokine-
refractory
(n = 276)
<70 years 20.2 mo (95% CI
16.2–25.1)
P70 years 15.8 mo (95% CI
13.7 – 24.0)
Sunitinib [46] review, P1st line First line Median 74 years
(range 70–88)
NA NA 17.8 months
Psecond line 18.3 months
Sorafenib vs placebo [47] P2nd
line
Sorafenib
(n = 451)
Median 59 years,
P65 years:
29.9%
HR 0.77 (95% CI 0.63–0.95) NR NR
Placebo
(n = 452)
Sorafenib [51] expanded access,
P1st line
Sorafenib
(n = 2504)
Median 63
(range 13–93)
P70 years:
29.4%
NR 50 weeks (95% CI: 47–
53 weeks)
46 weeks (95% CI:
42–53 weeks)
Temsirolimus vs temsirolimus
+ IFN vs IFN [61] phase III, 1st
line
Temsirolimus
(n = 209)
Median 58 years
(range 32–81)
10.9 mo (95% CI 8.6–12.7) NR HR > 1.0 for temsirolimus
compared to IFN in elderly
P65 yearsTemsirolimus
+ IFN
(n = 210)
Median 59 years
(range 32–82)
8.4 o (95% CI 6.6–10.3)
IFN (n = 207) Median 60 years
(range 23–86)
7.3 mo (95% CI 6.1–8.8)
Nivolumab vs everolimus [69]
phase III, post 1 or 2 regimens
anti-angiogenesis
Nivolumab
(n = 410)
Median 62 years
(range 23–88)
25 mo (95%
CI 21.8–not
estimable)
HR 0.73
(98.5% CI
0.57–0.93)
<65 years HR 0.78 (0.60–1.01) P65 to <75 years HR 0.64
(0.45–0.91)
Everolimus
(n = 411)
Median 62 years
(range 18–86)
19.6 mo (95%
CI 17.6–23.1)
P75 years HR 1.23
(0.66–2.31)
Abbreviations: NR = not reported, NA = not available, HR = hazard ratio, CI = confidence interval, vs = versus mo = months, IFN = interferon, TKI = tyrosine kinase inhibitor.
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access trial, 736 (29%) were aged over 70 years [51]. Treatment
efficacy in terms of PFS and OS was similar between the age
groups. Dose reduction, treatment interruption and treatment dis-
continuation rate was comparable in patients P70 and <70 years
and the rates of the most common adverse events of Pgrade 3
were similar, including cardiovascular events, fatigue and fatal
toxicity.
Efficacy of first-line systemic treatment with sunitinib, sorafe-
nib and bevacizumab in elderly patients with mRCC was evaluated
within a database consortium. No difference was found between
younger and older age groups [52].
Pazopanib
Pazopanib is a second generation TKI inhibiting VEGFR and
PDGFR. In a phase III trial comparing pazopanib with placebo in
treatment-naive and cytokine pre-treated mRCC patients, both
elderly (n = 154 patients P65 years) and younger patients
(n = 281 patients <65 years) had prolonged PFS on pazopanib com-
pared to placebo, with a HR of 0.46 for the whole population (95%
CI 0.34–0.62). No difference in toxicity profile between the age
groups was reported [53].
Pazopanib has been compared with sunitinib as first-line ther-
apy in a randomized trial of 1110 mRCC patients and proven
non-inferior regarding PFS [54]. Subgroup analysis revealed no dif-
ference for patients of 65 years and older (n = 434, 39%) compared
to younger patients. The toxicity profile, and health related qualityof life was in favor of pazopanib, however with a continuous dosing
schedule for pazopanib and a 4 week on, 2 week off schedule for
sunitinib, these data are difficult to interpret. No separate informa-
tion on toxicity and quality of life for elderly was reported.
Axitinib
Axitinib is a second generation TKI that selectively blocks
VEGFR-1, -2 and -3 with a high potency. A phase III trial random-
ized treatment-naive mRCC patients between axitinib (n = 192)
and sorafenib (n = 92) [55]. The median age in this trial was 58
(range 20–83), and for both the 219 patients <65 years of age
and the 69 patientsP65, PFS did not differ between the treatment
arms.
Another phase III trial compared axitinib with sorafenib as
second-line therapy in mRCC [56]. The median PFS was 6.7 months
for axitinib versus 4.7 months for sorafenib. The HR for PFS was
similar for patients P65 years of age and younger patients. No
information was provided about toxicity stratified for age.
Recommendations: All angiogenesis inhibitors appear to have
similar efficacy in elderly and younger patients. Available data
are summarized in Fig 1. Bevacizumab combined with interferon,
sunitinib and sorafenib have slightly worse toxicity profiles in
elderly. For pazopanib and axitinib toxicity data in elderly are
not available. Therefore, angiogenesis inhibitors can be used in
elderly, but patients should be followed closely for evaluation of
side effects. Most evidence in elderly is available for sunitinib as
first-line regimen and sorafenib as second-line regimen.
Table 3
Adverse events of approved systemic treatments for mRCC in elderly patients.
Trial Results
Bevacizumab + IFN vs placebo + IFN [39] phase III, 1st line NR
Bevacizumab + IFN vs IFN [40] phase III, 1st line NR
Bevacizumab + IFN vs IFN [41] phase III, 1st line NR
Bevacizumab + IFN [42] subgroup analysis of [40] AE incidence equal to younger adults, but incidence of grade P3 AEs was
higher. Also more fatigue and asthenia
Sunitinib vs IFN [43] phase III, 1st line NR
Sunitinib [44] expanded access Incidences of most commonly reported grade 3–4 related AEs did not differ in
elderly patients compared to the total population
Sunitinib [45] pooled data, P1st line Overall, the incidence profile of common AEs was broadly similar. However,
older patients are more likely to have a highest severity AE of grade 3, while for
younger patients a greater proportion had highest severity of grade 1 or 2. There
was no difference in the occurrence of highest grade 4 or 5. Significantly more
frequent related AEs: fatigue, cough, peripheral edema, anemia, decreased
weight, decreased appetite, thrombocytopenia, dizziness, hypothyroidism,
dehydration, UTI. Less hand-foot syndrome (24% vs 32%)
Sunitinib [46] Compared to [44,45] Fatigue/asthenia and mucositis occur more often in elderly compared to the
whole group, resp. 80.9% vs 37% and mucositis 61.8% vs 28%. Twice as much
dose reductions occurred (>2/3). Cardiac events 13%, compared to estimated
3%
Sorafenib vs placebo [47,48] P 2nd line Grade 3 toxicity in 40.0% vs 29.4% in younger adults. More fatigue and
gastrointestinal symptoms, but less hypertension, sensory neuropathy and
pruritis in patients that received sorafenib. 21.4% permanently discontinued
treatment vs 8.1%, dose reductions occurred in 21.4% vs 11.3%
Sorafenib [50] expanded access, P2nd line Incidence and severity comparable with overall population. 16% drug-related
SAEs vs 14% in younger patients. Compared to younger patients, more fatigue
Sorafenib [51] expanded access, P1st line Compared to younger patients, elderly patients more often discontinued
treatment due to AE with also slightly more dose reductions. Most common
grade P3 AEs were similar, however, drug-related cardiovascular events grade
P3 occurred more often in elderly. More gradeP3 fatigue. SAEs and proportion
of deaths were equal
Pazopanib [53] phase III, 1st line or post-cytokines NR
Pazopanib vs sunitinib [54] phase III, 1st line NR
Axitinib vs sorafenib [55] phase III, 1st line NR
Axitinib vs sorafenib [56] phase III, post sunitinib, bevIFN, temsirolimus or cytokines NR
Everolimus vs placebo [58,59] phase III, post TKI + subgroup analysis Similar, with generally consistent grade 3/4 rates between the whole
population and elderly. Most common grade 3/4 in elderly: anemia, infection,
lymphopenia, hyperglycemia. Higher rates peripheral edema, cough, rash,
diarrhea. Age did not affect SAE incidence. Patients P70 more often dose
reductions and/or interruptions, resulting in lower mean dose intensity
Temsirolimus [61] phase III, 1st line NR
Temsirolimus [63] phase III, 1st line NR
Nivolumab vs everolimus [69] phase III, post 1 or 2 regimens anti-angiogenesis NR
Abbreviations: AEs = adverse events, SAEs = serious adverse events, UTI = urinary tract infection.
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Another important oncogenic pathway that is frequently upreg-
ulated in RCC is the mTOR pathway [57]. mTOR is involved in cell
proliferation, cell growth and survival and angiogenesis.Everolimus
Everolimus is an orally administered inhibitor of mTOR. A phase
III trial comparing everolimus with placebo, showed a prolongation
of PFS from 1.9 to 4.9 months in mRCC patients [58]. There was how-
ever no difference in the time to definitive deterioration of patient
reported outcomes or OS. The efficacy and safety of everolimus in
elderly patients who participated in the trial was analyzed separately
[59]. Analyses were performed both for patients agedP65 years and
for patientsP70 years of age. PatientsP65 years of age had a med-
ian PFS of 5.4 months in the everolimus arm (n = 111) and
2.2 months in the placebo arm, for patients P70 years of age this
was 5.1 (n = 52) versus 1.9 months. In all everolimus-treated patients
(n = 274), only 1.8% had a partial tumor response and no responses
were observed in the placebo group. Overall response rates were
2.7% for patientsP65 and 3.8% for those P70 years of age.
Consistent with the complete study population, no difference in
median OS was observed in everolimus-treated patients compared
with those receiving placebo in patients agedP65 andP70 years.Everolimus was well tolerated by elderly, with low rates of
grade 3–4 adverse events. However, more dose-interruptions were
needed in the elderly patients; in 55.8% of patientsP70 years and
in 49.5% of patients P65 years of age one or more dose-
interruptions were needed whereas 46.4% of all patients had treat-
ment interruptions. Some adverse events were more frequent in
elderly patients, irrespective of treatment, including peripheral
edema, cough, rash, and diarrhea. Importantly, no increase in
everolimus-related pneumonitis was observed compared with
younger patients.
Between July 2008 and June 2010 1367 mRCC patients with
intolerance to or progressive disease on VEGFR-TKI therapy were
enrolled in an expanded access program with everolimus. The
study reported that patients P65 years of age were less likely to
be on treatment for more than 6 months compared to younger
patients [60].Temsirolimus
Temsirolimus is an intravenously administered mTOR inhibitor.
In a 3-arm study in patients with poor-prognosis mRCC, tem-
sirolimus (25 mg weekly intravenously), was compared with
interferon-a2a (3 MIU increasing to a target dose of 18 MIU 3 times
weekly subcutaneously) and the combination (temsirolimus 15 mg
weekly plus interferon-a2a 6 MIU 3 times weekly) [61]. Single
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Fig. 1. Modified NCCN evidence blocks for elderly (left) compared to the official
NCCN evidence block (right). Column Q was modified for the elderly. The other
columns kept the original definition. E = Efficacy of Regimen/Agent. S = Safety of
Regimen/Agent. Q = Quality of Evidence. C = Consistency of Evidence. A = Afford-
ability of Regimen/Agent. Quality and quantity of evidence in elderly: 5 Meta-
analysis in elderly, 4 Separate publication(s) comparing efficacy and toxicity in
older adult patients to the overall or younger patient population ofP1 randomized
phase III trial(s) or expanded access trial(s). 3 Separate publication on efficacy and
toxicity in older adult patients without comparison to the overall or younger
patient population. 2 Subgroup analysis in >1 randomized phase III trials or
expanded access trials 1. Subgroup analysis in 1 randomized phase III trial or
expanded access trial.
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tion compared to interferon-a2a alone. The combination of tem-
sirolimus plus interferon-a2a did not improve OS. For the
subgroup of elderly patients treated with temsirolimus alone
(n = 64) compared to interferon-a2a alone (n = 65) however, the
HR for death was >1.0. Information about toxicity related to age
was not mentioned in this study.
A retrospective analysis showed that serum LDH above the
upper limit of normal was a negative prognostic but a positive pre-
dictive biomarker for survival benefit of temsirolimus over
interferon-a2a [62]. Patients with a high LDH were more likely
to be younger of age than patients with a normal LDH, which might
have contributed to the lack survival benefit of temsirolimus over
interferon-a2a in elderly in this study.
No difference in efficacy was found between temsirolimus plus
bevacizumab versus interferon plus bevacizumab in mRCC patients
[63].
Recommendations: Everolimus can be prescribed to elderly
mRCC patients who progressed on VEGF targeting therapy but
these patients should be closely followed for toxicity. Elderly
patients with poor prognosis mRCC do not seem to benefit from
temsirolimus, see Fig. 1.Aging and immunity
With ageing, immune senescence and immune exhaustion of T
cells occur. Exhaustion is characterized by loss of essential func-
tional activity necessary for immune protection and senescence
is a loss of replicative capacity of antigen-specific T cell popula-
tions [24]. These processes are considered a consequence of
repeated antigenic stimulation during life. The resulting declined
immune function in elderly might contribute to development and
progression of cancer. RCC is considered an immunogenic malig-
nancy [64] and boosting immune function is clearly of interest to
improve the outcome for patients with advanced disease.
Cytokine therapy induces non-specific activation of the immune
system resulting in low rates but sometimes long lasting tumor
responses. To increase the likelihood of anti-tumor activity, novel
targeted immune checkpoint blockade aims to improve tumor
specific T cell activity. Recently, the PD-1 antibody nivolumab
has been approved by the Food and Drug Administration for
patients with advanced RCC patients who have received prior
anti-angiogenic therapy. First-line immune checkpoint inhibitor
studies are ongoing as well as combination studies including anti-
bodies against PD-1 or its ligand PD-L1, cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4). It would be of interest to evaluate
whether efficacy of immune checkpoint inhibitors differs between
age groups.Cytokine therapy
Interferon-a and interleukin-2 (IL-2) were the standard of treat-
ment for mRCC before the era of targeted therapy. Elderly patients
appeared to do no worse than younger patients [65–67], but with
the introduction of angiogenesis inhibitors, there is no role any-
more for single agent cytokine therapy.PD-1 and PD-L1 inhibitors
To escape auto-immunity, tumor cells can express a PD-1
ligand. Those ligands bind to the immune checkpoint protein
PD-1 on T cells, resulting in T cell anergy. Reversing immune
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strated antitumor activity in mRCC and several other cancer types.
Interestingly, mRCC patients with overexpression of PD-L1 in
the primary tumor have a shorter median PFS when treated with
sunitinib compared to patients without PD-L1 overexpression (10
versus 19 months, P = 0.01) [68].
In the CheckMate 025 study, a phase III randomized trial com-
paring nivolumab with everolimus in mRCC patients previously
treated with a VEGFR-TKIs, 821 patients were randomized [69].
They received nivolumab 3 mg/kg IV every 2 weeks or everolimus
10 mg/day orally. OS was 25.0 months for nivolumab versus
19.6 months for everolimus, with a HR for death of 0.73 (95% CI
0.57–0.93). The unstratified HR for death was 0.78 (0.60–1.01)
for patients <65 years (n = 497), 0.64 (0.45–0.91) for patients
P65 to 75 years (n = 250) and 1.23 (0.66–2.31) for patients
P75 years of age (n = 73). In 79% of patients receiving nivolumab
an adverse event occurred; the most common adverse events were
fatigue, nausea and pruritis. No distinction was made between age
groups.
A dose escalation phase I trial assessed safety and activity of
BMS-936559, a monoclonal antibody directed against PD-L1 [70],
included 17 patients with mRCC. All mRCC patients received
10 mg/kg, and 2 objective responses were observed. Seven patients
had stable disease at 24 weeks, and the PFS rate was 53% at
24 weeks.
A phase I trial with MDPL3280A, another PD-L1 antibody,
included 53 mRCC patients evaluable for toxicity with a median
age of 62 (range 33–79) [71]. Grade 3–4 toxicity caused by
MDPL3280A was found in 13% of the patients. Thirty-nine patients
were evaluable for efficacy, showing a 24-week PFS of 50%.
From these studies it can be concluded that immunotherapy is a
breakthrough for mRCC. Even in heavily pre-treated patients
efficacy is documented. More studies are ongoing and results are
eagerly awaited, especially about the role of immunotherapy as
first-line treatment. Of special interest are also combination
regimens with anti-angiogenic agents and immunotherapy (clini-
caltrials.gov NCT02420821, NCT02348008, NCT002210117,
NCT02133742, NCT01984242, NCT02014636, NCT01472081). So
far, only limited subgroup analyses for age were performed in
immunotherapy trials, which is clinically highly relevant. Below
we present some data in other tumor types.
CTLA-4 inhibitors
Ipilimumab is a monoclonal antibody against CTLA-4. Blocking
the immune checkpoint protein CTLA-4 sustains T cell activation,
thereby enhancing autoimmune activity. In a phase II study 61
mRCC patients received either 3 mg/kg ipilimumab intravenously
followed by 1 mg/kg or all doses at 3 mg/kg every 3 weeks [72].
Thirty-three percent of the patients experienced grade 3–4 autoim-
mune mediated toxicity such as enteritis and endocrine deficien-
cies. Six patients experienced a partial response, and responses
were seen in patients who had not responded to high-dose IL-2
treatment. Patient age ranged from 31 to 70 years, with median
age under 60. No age related data was described.
Efficacy and toxicity of immune checkpoint inhibitors in elderly
melanoma and non small cell lung cancer patients
In the CheckMate 067 study, comparing nivolumab, ipilimumab
and nivolumab + ipilimumab in patients with advancedmelanoma,
a subgroup analysis was done for patients <65 (n = 565), P65 to
<75 (n = 262) and P75 (n = 118). No meaningful differences were
found in the incidence of side effects between the groups. The
PFS of patients <65 years of age was 11.7 months (combination),
5.5 months (nivolumab) and 2.8 months (ipilimumab). For patientsP65 to <75 this was 11.1 months, 12.7 months and 2.9 months.
Average PFS could not be determined for patientsP75 on the com-
bination treatment because these patients had not progressed yet.
PFS in this subgroup was 5.3 months (nivolumab) and 4.0 months
(ipilimumab) [73]. A subset analysis was performed to assess
safety and efficacy of nivolumab in elderly with melanoma, in
which patients <65 and P65 years of age were compared. There
was neither a difference in immune related adverse events, nor
in OS. Moreover, a significant OS benefit was seen in patients of
all ages experiencing any grade of immune related adverse event
[74]. In non-squamous non-small-cell lung cancer, a phase III trial
comparing nivolumab to docetaxel showed improved OS for nivo-
lumab, with unstratified HR of 0.81 (0.62–1.04) for patients
<65 year (n = 339), 0.63 (0.45–0.89) for patients P65 to <75 year
(n = 200) and 0.90 (0.43–1.87) for patients P75 year (n = 43). No
toxicity results stratified for age were published [75].
Recommendations: Very limited data suggest that nivolumab
might be less effective in patientsP75 year. Clinicians should take
life expectancy and expected ability to cope with side effects into
account, when deciding whether or not to recommend nivolumab
treatment to elderly.
Discussion
Approximately 50% of the patients with mRCC are elderly. With
multiple systemic treatment options available, instruments rating
clinical benefit are highly relevant. For this purpose, the NCCN
developed evidence blocks, ESMO developed a magnitude of clini-
cal benefit scale and ASCO introduced a value framework. How-
ever, these tools are created for the entire patient population and
are not necessarily applicable to elderly. We presented modified
evidence blocks with for elderly mRCC patients. This grading for
the elderly is neither created by a panel of experts nor has it been
validated, but it is meant as an illustration and should be inter-
preted with caution.
Regretfully for several treatment options, solid proof for the use
in elderly is lacking. Next to underrepresentation of elderly in clin-
ical trials, often results of subgroup analyses for elderly that partic-
ipated in the trials are not published. Over time a transition is
warranted where collecting and publishing data representing the
treatment effects in elderly becomes self-evident. The power of
building warehouses to retrieve information is increasingly appre-
ciated [76]. It might be of interest to stock a warehouse with data
of mRCC patients who participated in prospective studies. This
would allow dedicated research groups to retrieve efficacy and
safety data of different mRCC regimens in large numbers of the
elderly patients and accommodate the unmet need of solid proof
in elderly.
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